Site içinde arama yapın

bir dosya eklendi Health

2026-02-16 05:48:35 -

The "Targeted" Strike: How 2026 is Mastering the HER2 and FGFR2 Pathways.

By mid-2026, the industry has officially entered the era of "Biomarker-Driven Precision." This year, the focus is on the record-breaking success of Zanidatamab and Trastuzumab deruxtecan for treating HER2-positive gallbladder tumors. This innovation is a primary driver for the market, as these targeted agents allow patients with specific genetic "tags" to bypass the harsh side effects of...

0 Yorumlar 0 hisse senetleri 363 Views